OCGN – Ocugen, Inc.
OCGN — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
16.39
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
0.01
EPS Last/This Y
0.02
EPS This/Next Y
0.26
Price
1.75
Target Price
11.57
Analyst Recom
1
Performance Q
20
Upside
-562.6%
Beta
2.52
Ticker: OCGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | OCGN | 1.675 | 0.14 | 0.24 | 63565 |
| 2026-03-10 | OCGN | 1.765 | 0.14 | 0.09 | 63772 |
| 2026-03-11 | OCGN | 2.295 | 0.14 | 0.14 | 64763 |
| 2026-03-12 | OCGN | 2.345 | 0.15 | 0.10 | 72712 |
| 2026-03-13 | OCGN | 2.34 | 0.15 | 0.10 | 72712 |
| 2026-03-17 | OCGN | 2.46 | 0.16 | 0.07 | 77358 |
| 2026-03-18 | OCGN | 2.3 | 0.15 | 0.16 | 86766 |
| 2026-03-19 | OCGN | 2.24 | 0.14 | 0.12 | 88342 |
| 2026-03-20 | OCGN | 2.03 | 0.15 | 0.15 | 88929 |
| 2026-03-23 | OCGN | 2.11 | 0.13 | 0.11 | 74873 |
| 2026-03-24 | OCGN | 1.91 | 0.13 | 0.41 | 76228 |
| 2026-03-25 | OCGN | 1.95 | 0.13 | 0.29 | 76957 |
| 2026-03-26 | OCGN | 1.98 | 0.15 | 0.22 | 80592 |
| 2026-03-27 | OCGN | 1.88 | 0.15 | 1.26 | 81014 |
| 2026-03-30 | OCGN | 1.75 | 0.17 | 0.22 | 82349 |
| 2026-03-31 | OCGN | 1.815 | 0.17 | 0.23 | 82930 |
| 2026-04-01 | OCGN | 1.79 | 0.17 | 0.77 | 83826 |
| 2026-04-02 | OCGN | 1.785 | 0.17 | 0.56 | 84154 |
| 2026-04-06 | OCGN | 1.765 | 0.17 | 0.01 | 84597 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | OCGN | 1.67 | -15.0 | - | -0.23 |
| 2026-03-10 | OCGN | 1.76 | -15.0 | - | -0.23 |
| 2026-03-11 | OCGN | 2.30 | -15.0 | - | -0.23 |
| 2026-03-12 | OCGN | 2.35 | -15.0 | - | -0.23 |
| 2026-03-13 | OCGN | 2.48 | -10.0 | - | -0.23 |
| 2026-03-17 | OCGN | 2.46 | -8.0 | - | -0.22 |
| 2026-03-18 | OCGN | 2.30 | -8.0 | - | -0.22 |
| 2026-03-19 | OCGN | 2.24 | -8.0 | - | -0.22 |
| 2026-03-20 | OCGN | 2.03 | -6.7 | - | -0.22 |
| 2026-03-23 | OCGN | 2.11 | -6.7 | - | -0.22 |
| 2026-03-24 | OCGN | 1.91 | -6.7 | - | -0.22 |
| 2026-03-25 | OCGN | 1.95 | -6.7 | - | -0.22 |
| 2026-03-26 | OCGN | 1.98 | -6.7 | - | -0.22 |
| 2026-03-27 | OCGN | 1.88 | -6.7 | - | -0.22 |
| 2026-03-30 | OCGN | 1.75 | -3.3 | - | -0.21 |
| 2026-03-31 | OCGN | 1.82 | -3.3 | - | -0.21 |
| 2026-04-01 | OCGN | 1.79 | -3.3 | - | -0.21 |
| 2026-04-02 | OCGN | 1.79 | -3.3 | - | -0.21 |
| 2026-04-06 | OCGN | 1.76 | -3.3 | - | -0.21 |
| 2026-04-07 | OCGN | 1.75 | -3.3 | - | -0.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | OCGN | 0.00 | 5.13 | 15.36 |
| 2026-03-10 | OCGN | 0.00 | 5.13 | 15.36 |
| 2026-03-11 | OCGN | 0.00 | 5.13 | 15.84 |
| 2026-03-12 | OCGN | 0.00 | 5.13 | 15.84 |
| 2026-03-13 | OCGN | 0.00 | 5.13 | 15.84 |
| 2026-03-17 | OCGN | 0.00 | 5.17 | 15.84 |
| 2026-03-18 | OCGN | 0.00 | 5.17 | 15.84 |
| 2026-03-19 | OCGN | 0.00 | 5.17 | 15.84 |
| 2026-03-20 | OCGN | 0.00 | 5.17 | 15.84 |
| 2026-03-23 | OCGN | 0.00 | 5.17 | 15.84 |
| 2026-03-24 | OCGN | 0.00 | 5.17 | 15.84 |
| 2026-03-25 | OCGN | 0.00 | 5.17 | 16.39 |
| 2026-03-26 | OCGN | 0.00 | 5.17 | 16.39 |
| 2026-03-27 | OCGN | 0.00 | 5.17 | 16.39 |
| 2026-03-30 | OCGN | 0.00 | 5.17 | 16.39 |
| 2026-03-31 | OCGN | 0.00 | 5.17 | 16.39 |
| 2026-04-01 | OCGN | 0.00 | 5.17 | 16.39 |
| 2026-04-02 | OCGN | 0.00 | 5.17 | 16.39 |
| 2026-04-06 | OCGN | 0.00 | 5.18 | 16.39 |
| 2026-04-07 | OCGN | 0.00 | 5.18 | 16.39 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.06
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
5.18
Beta
2.52
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
8
Growth Score
34
Sentiment Score
49
Actual DrawDown %
90.1
Max Drawdown 5-Year %
-97.7
Target Price
11.57
P/E
Forward P/E
30.7
PEG
P/S
129.37
P/B
P/Free Cash Flow
EPS
-0.23
Average EPS Est. Cur. Y
-0.21
EPS Next Y. (Est.)
0.04
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1537.41
Relative Volume
0.59
Return on Equity vs Sector %
530.2
Return on Equity vs Industry %
546.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
◆
OCGN
Healthcare
$1.74
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43
Range 1M
19.8%
Sup Dist
0.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
5.6%
EPS NY
126.1%
52W%
55.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+147.5% upside
Upside
+147.5%
Quality
8
Ocugen, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 116
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
OCGN
Latest News
—
Caricamento notizie per OCGN…
stock quote shares OCGN – Ocugen, Inc. Stock Price stock today
news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCGN – Ocugen, Inc. yahoo finance google finance
stock history OCGN – Ocugen, Inc. invest stock market
stock prices OCGN premarket after hours
ticker OCGN fair value insiders trading